Fortifier

A technology of enhancer and inhibitor, applied in the field of drugs for the treatment or prevention of kidney disease, can solve the problem of unrecognized effects, and achieve excellent inhibitory effect, effective treatment, and safe treatment.

Active Publication Date: 2006-06-07
TORAY IND INC
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to the report in this literature, compared with the control group, the group using the two drugs alone has less renal function parameters such as proteinuria, or renal tissue lesions, but even if the two drugs are used in combination, it is better than that when the two drugs are used alone. The effect has not been recognized, and it is considered that there is no combined effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fortifier
  • Fortifier
  • Fortifier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] Example 1 Rabbit anti-rat glomerular basement membrane antiserum (NTS, diluted 10 times, 3ml / kg) was administered to 9-week-old WKY rats derived from Japan's Chuya-ruzuliba-induced glomerulonephritis. Two weeks later, urine and blood were collected, and the test animals were divided into 6 groups according to the amount of urine protein and serum creatinine value, and the administration was started. At this time, the serum creatinine value has risen, and it can be judged that it can be classified as the stage of renal failure. Renal function was evaluated based on serum creatinine values.

[0134] 1) Control group: only given solvent, n=6

[0135] 2) BPS100 group (comparative example): Bereprosodium 100 μg / kg (BID: this dosage is given twice a day), n=6

[0136] 3) BPS300 group (comparative example): Berepro sodium 300 μg / kg (BID), n=6

[0137] 4) Candesartan 10 group (comparative example): candesartan cilexetil 10 mg / kg (OAD: this dosage is given once a day), n=6

...

Embodiment 2

[0145] Example 2 Nephritis was induced by administering rabbit anti-rat glomerular basement membrane antiserum to 9-week-old WKY rats. Two weeks after the administration of the antiserum, the test animals were divided into the following 4 groups, and the administration was started.

[0146] 1) Control group: 0.5% CMC (OAD) + distilled water (BID), n=6

[0147] 2) Telmisartan group (comparative example): Telmisartan 40 mg / kg (OAD) + distilled water (BID), n=5

[0148] 3) BPS group (comparative example): 0.5% CMC (OAD) + bereprosodium 100 μg / kg (BID), n=5

[0149] 4) Telmisartan+BPS group (the present invention): Telmisartan 40 mg / kg (OAD) + Berepro sodium 100 μg / kg (BID), n=6.

[0150] As shown in Table 1, there was almost no difference in the effect of suppressing the progression of renal failure in the BPS group compared with the control group. Both telmisartan group and telmisartan+BPS group could inhibit the worsening of renal failure, and the inhibitory effect of telmis...

Embodiment 3

[0154] Nephritis was induced by administering rabbit anti-rat glomerular basement membrane antiserum to 9-week-old WKY rats. Two weeks after the administration of the antiserum, the test animals were divided into the following 4 groups, and the administration was started.

[0155] 1) Control group: 0.5% CMC (BID) + distilled water (BID), n=6

[0156] 2) Losartan group (comparative example): Losartan 30mg / kg (BID) + distilled water (BID), n=5

[0157] 3) BPS group (comparative example): 0.5% CMC (BID) + bereprosodium 100 μg / kg (BID), n=6

[0158] 4) Losartan+BPS group (the present invention): Losartan 30 mg / kg (BID) + Berepro sodium 100 μg / kg (BID), n=5

[0159] Serum creatinine was measured 6 weeks after nephritis was induced to evaluate the degree of deterioration of renal failure. As shown in Table 2, compared with the control group, the losartan group and the BPS group at this dosage have no difference in the inhibitory effect on the deterioration of renal failure. On t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a nephropathy treating or preventing effect enhancer of candesartan cilexetil and other renin-angiotensin system inhibitors. The enhancer contains specific prostaglandin I derivatives such as bereprosodium as active ingredients.

Description

technical field [0001] The present invention relates to a drug for treating or preventing nephropathy, in particular to an enhancer for treating or preventing nephropathy of a renin-angiotensin system inhibitor. Background technique [0002] In recent years, the number of patients with kidney disease has been increasing. The causes thereof include changes in the living environment, aging, and the increase in diabetic nephropathy due to the increase in diabetic patients in recent years. The number of patients who have to undergo dialysis for renal failure due to the decline of renal function is increasing every year. In addition to the need to go to the hospital every 2 to 3 weeks in dialysis therapy, there are many complications such as red blood cell production and maturation disorders, accumulation of aluminum and β2 microglobulin accompanying long-term dialysis, and increase in cardiovascular diseases. unresolved issues. In particular, the 5-year survival rate of patie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5585A61K31/4184A61K45/00A61K45/06A61P9/12A61P13/12C07D307/93C07D403/10
CPCA61K31/401A61K31/403A61K31/404A61K31/4178A61K31/4184A61K31/5585A61K45/06A61P9/12A61P11/00A61P13/12A61P43/00C07D307/93A61K2300/00A61K31/343A61K47/22
Inventor 车谷元田村光孝
Owner TORAY IND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap